1158 IDENTIFICATION OF A GENE SET PANEL ON URINE SAMPLES FOR THE NONINVASIVE DIAGNOSIS AND AGGRESSIVENESS ASSESSMENT OF BLADDER UROTHELIAL CARCINOMA

Abstract

You have accessJournal of UrologyBladder Cancer: Detection and Screening1 Apr 20101158 IDENTIFICATION OF A GENE SET PANEL ON URINE SAMPLES FOR THE NONINVASIVE DIAGNOSIS AND AGGRESSIVENESS ASSESSMENT OF BLADDER UROTHELIAL CARCINOMA Lourdes Mengual, Moises Burset, Maria J. Ribal, Elisabet Ars, Mercedes Marín-Aguilera, Manuel Fernández, Mercedes Ingelmo-Torres, Humberto Villavicencio, and Antonio Alcaraz Lourdes MengualLourdes Mengual More articles by this author , Moises BursetMoises Burset More articles by this author , Maria J. RibalMaria J. Ribal More articles by this author , Elisabet ArsElisabet Ars More articles by this author , Mercedes Marín-AguileraMercedes Marín-Aguilera More articles by this author , Manuel FernándezManuel Fernández More articles by this author , Mercedes Ingelmo-TorresMercedes Ingelmo-Torres More articles by this author , Humberto VillavicencioHumberto Villavicencio More articles by this author , and Antonio AlcarazAntonio Alcaraz More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.658AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To develop an accurate and noninvasive method for bladder cancer diagnosis and prediction of disease aggressiveness based on the gene expression patterns of urine samples. METHODS Gene expression patterns of 341 urine samples from bladder urothelial cell carcinoma (UCC) patients and 235 controls were analyzed by means TaqMan Arrays. In a first phase of the study, 3 consecutively gene selection steps were performed to identify a gene set expression signature to detect and stratify UCC in urine. Subsequently, those genes more informative for UCC diagnosis and prediction of tumor aggressiveness were combined to obtain a classification system of bladder cancer samples. In a second phase, the obtained gene set signature was evaluated in a clinical routine scenario analyzing only voided urine samples. RESULTS We have identified a 12+2 gene expression signature for UCC diagnosis and prediction of tumor aggressiveness on urine samples. Overall, this gene set panel had 98% sensitivity (SN) and 99% specificity (SP) in discriminating between UCC and control samples and 79% SN and 92% SP in predicting tumor aggressiveness. The translation of the model to the clinically applicable format corroborate that the 12+2 gene set panel described maintains a high accuracy for UCC diagnosis (SN=89% and SP=95%) and tumor aggressiveness prediction (SN=79% and a SP=91%) in voided urine samples. CONCLUSIONS The 12+2 gene expression signature described in urine is able to identify patients suffering from UCC and predict tumor aggressiveness. We show that a panel of molecular markers can improve the schedule for diagnosis and follow-up in UUC patients. Barcelona, Spain© 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e448 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Lourdes Mengual More articles by this author Moises Burset More articles by this author Maria J. Ribal More articles by this author Elisabet Ars More articles by this author Mercedes Marín-Aguilera More articles by this author Manuel Fernández More articles by this author Mercedes Ingelmo-Torres More articles by this author Humberto Villavicencio More articles by this author Antonio Alcaraz More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...